Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Erin Bange,Abigail Doucette,Peter Gabriel,Florence Porterfield,James J. Harrigan,Robin Wang,A.P. Wojcieszynski,Ben Boursi,Bethany I. Mooney,Kim A. Reiss,Ronac Mamtani

Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

2020

Erin Bange
Abigail Doucette
Peter Gabriel
Florence Porterfield
James J. Harrigan
Robin Wang
A.P. Wojcieszynski
Ben Boursi
Bethany I. Mooney
Kim A. Reiss
Ronac Mamtani

PURPOSE:The median overall survival (OS) for metastatic pancreatic ductal adenocarcinoma (mPDAC) is < 1 year. Factors that contribute to quality of life during treatment are critical to quantify. O...

Keywords:

Quality of life
Oncology
Internal medicine
Chemotherapy
pancreatic ductal adenocarcinoma
Medicine
overall survival
palliative chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations